Applying to ACC for Hepatitis C treatment funding
Pharmac have recently approved funding for Hepatitis C treatment ViekiraPAK and ViekiraPAK/RBV, and these are listed on the Pharmaceutical Schedule. This means that treatment is funded for all patients with Hepatitis C virus genotype 1. Harvoni is available for patients who meet the Pharmac special authority criteria. ACC clients are eligible for the Hepatitis C treatments listed in the Pharmaceutical Schedule.
ACC may consider funding Hepatitis C treatments for our covered clients who do not meet the criteria in the Pharmaceutical Schedule. You can check the Pharmaceutical Schedule funding criteria on the Pharmac website:
To apply to ACC for funding for this treatment, or if you have any questions, please contact Angela Carter by:
ACC Claims Manager
Treatment Assessment Centre
PO Box 408
If you have any questions, you can contact Angela: